182 related articles for article (PubMed ID: 37656441)
21. Treatment of Idiopathic Castleman Disease.
van Rhee F; Greenway A; Stone K
Hematol Oncol Clin North Am; 2018 Feb; 32(1):89-106. PubMed ID: 29157622
[TBL] [Abstract][Full Text] [Related]
22. Clinical features and treatment of 7 Chinese TAFRO syndromes from 96 de novo Castleman diseases: a 10-year retrospective study.
Zhang Y; Suo SS; Yang HJ; Zhou XP; You LS; Yu WJ; Wang ZM; Jin J
J Cancer Res Clin Oncol; 2020 Feb; 146(2):357-365. PubMed ID: 31938902
[TBL] [Abstract][Full Text] [Related]
23. Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy.
Cohen PR; Nikanjam M; Kato S; Goodman AM; Kurzrock R
Cureus; 2020 Jul; 12(7):e8967. PubMed ID: 32766009
[TBL] [Abstract][Full Text] [Related]
24. Characteristics of thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly syndrome: a retrospective study from a large Western cohort.
Maisonobe L; Bertinchamp R; Damian L; Gérard L; Berisha M; Guillet S; Fieschi C; Malphettes M; Fadlallah J; Hié M; Dunogué B; De Wilde V; Vandergheynst F; Zafrani L; Grall M; Saada N; Garzaro M; Oksenhendler E; Galicier L; Boutboul D
Br J Haematol; 2022 Feb; 196(3):599-605. PubMed ID: 34585382
[TBL] [Abstract][Full Text] [Related]
25. Kidney biopsy findings in two patients with TAFRO syndrome: case presentations and review of the literature.
Zhou Q; Zhang Y; Zhou G; Zhu J
BMC Nephrol; 2020 Nov; 21(1):499. PubMed ID: 33225930
[TBL] [Abstract][Full Text] [Related]
26. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials.
van Rhee F; Casper C; Voorhees PM; Fayad LE; Gibson D; Kanhai K; Kurzrock R
Lancet Haematol; 2020 Mar; 7(3):e209-e217. PubMed ID: 32027862
[TBL] [Abstract][Full Text] [Related]
27. Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review.
Belyaeva E; Rubenstein A; Pierson SK; Dalldorf D; Frank D; Lim MS; Fajgenbaum DC
Hematol Oncol; 2022 Apr; 40(2):191-201. PubMed ID: 35104370
[TBL] [Abstract][Full Text] [Related]
28. A Multicentric Castleman Disease Associated with Mixed Warm and Cold Antibody-Mediated AHA Responsive to Siltuximab.
Plano F; Mancuso S; Camarda GM; Butera MG; Sucato G; Alecci G; Florena AM; Perrone S; Siragusa SM
Chemotherapy; 2024; 69(1):35-39. PubMed ID: 37634492
[TBL] [Abstract][Full Text] [Related]
29. TAFRO Syndrome and Elusive Diagnosis of Idiopathic Multicentric Castleman Disease Treated with Empiric Anti-Interleukin-6 Therapy.
Williams C; Phillips A; Aggarwal V; Slonim LB; Fajgenbaum DC; Karmali R
Case Rep Oncol; 2021; 14(3):1359-1365. PubMed ID: 34720942
[TBL] [Abstract][Full Text] [Related]
30. [PET-CT documented remission of multicentric Castleman disease after treatment with rituximab: case report and review].
Adam Z; Szturz P; Koukalová R; Řehák Z; Pour L; Krejčí M; Šmardová L; Eid M; Volfová P; Čermáková Z; Křen L; Sokol F; Hanke I; Michalková E; Král Z; Mayer J
Vnitr Lek; 2015 Mar; 61(3):251-9. PubMed ID: 25873122
[TBL] [Abstract][Full Text] [Related]
31. Idiopathic multicentric Castleman disease with positive antiphospholipid antibody: atypical and undiagnosed autoimmune disease?
Nishimura Y; Nishikori A; Sawada H; Czech T; Otsuka Y; Nishimura MF; Mizuno H; Sawa N; Momose S; Ohsawa K; Otsuka F; Sato Y
J Clin Exp Hematop; 2022 Jun; 62(2):99-105. PubMed ID: 35249898
[TBL] [Abstract][Full Text] [Related]
32. Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival.
Gao YH; Liu YT; Zhang MY; Li SY; Fajgenbaum DC; Zhang L; Li J
Br J Haematol; 2024 May; 204(5):1830-1837. PubMed ID: 38356434
[TBL] [Abstract][Full Text] [Related]
33. Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease.
Fajgenbaum DC; Kurzrock R
Immunotherapy; 2016; 8(1):17-26. PubMed ID: 26634298
[TBL] [Abstract][Full Text] [Related]
34. A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study.
Yu L; Shi M; Cai Q; Strati P; Hagemeister F; Zhai Q; Li L; Fang X; Li J; Sun R; Zhang S; Yang H; Wang Z; Qian W; Iwaki N; Sato Y; Zhang L; Li J; Oksenhendler E; Xu-Monette ZY; Young KH
Oncologist; 2020 Nov; 25(11):963-973. PubMed ID: 32852137
[TBL] [Abstract][Full Text] [Related]
35. Unicentric Castlemans disease. Symptoms, diagnostics and therapy.
Adam Z; Řehák Z; Adamová Z; Koukalová R; Pour L; Krejčí M; Boichuk I; Krejčí M; Štork M; Ševčíková S; Král Z
Vnitr Lek; 2021; 67(8):465-473. PubMed ID: 35459366
[TBL] [Abstract][Full Text] [Related]
36. Idiopathic Plasmacytic Lymphadenopathy Forms an Independent Subtype of Idiopathic Multicentric Castleman Disease.
Nishikori A; Nishimura MF; Nishimura Y; Otsuka F; Maehama K; Ohsawa K; Momose S; Nakamura N; Sato Y
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142213
[TBL] [Abstract][Full Text] [Related]
37. Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease.
Zhang L; Zhao AL; Duan MH; Li ZY; Cao XX; Feng J; Zhou DB; Zhong DR; Fajgenbaum DC; Li J
Blood; 2019 Apr; 133(16):1720-1728. PubMed ID: 30760451
[TBL] [Abstract][Full Text] [Related]
38. The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry.
Fajgenbaum DC; Pierson SK; Kanhai K; Bagg A; Alapat D; Lim MS; Lechowicz MJ; Srkalovic G; Uldrick TS; van Rhee F;
Br J Haematol; 2022 Jul; 198(2):307-316. PubMed ID: 35507638
[TBL] [Abstract][Full Text] [Related]
39. Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease.
Pierson SK; Shenoy S; Oromendia AB; Gorzewski AM; Langan Pai RA; Nabel CS; Ruth JR; Parente SAT; Arenas DJ; Guilfoyle M; Reddy M; Weinblatt M; Shadick N; Bower M; Pria AD; Masaki Y; Katz L; Mezey J; Beineke P; Lee D; Tendler C; Kambayashi T; Fosså A; van Rhee F; Fajgenbaum DC
Blood Adv; 2021 Sep; 5(17):3445-3456. PubMed ID: 34438448
[TBL] [Abstract][Full Text] [Related]
40. International definition of iMCD-TAFRO: future perspectives.
Nishimura Y; Nishimura MF; Sato Y
J Clin Exp Hematop; 2022 Jun; 62(2):73-78. PubMed ID: 35474036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
